Skip to main content
Skip to section navigation
Skip to footer
Close
Our Technology
Our Technology
Nu.Q
®
Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
Our Tests
Our Nu.Q
®
tests provide a cost effective routine blood test for disease detection, treatment and monitoring.
Our Tests
Human Health
Nu.Q
®
NETs
Nu.Q
®
NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
Nu.Q
®
Discover
Buy our Nu.Q
®
Discover H3.1 Research Use Only Assay
Animal Health
Nu.Q
®
Vet Cancer Test
Nu.Q
®
Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Our Service
Use our assays to answer your clinical questions, such as measuring treatment efficacy, or on-target and off-target effects in drug development.
Our Service
Nu.Q
®
Discover
Nu.Q
®
Discover gives you access to a range of assays, built on our proprietary Nucleosomics™ platform, for rapid epigenetic profiling in disease model development, preclinical testing and clinical studies.
Our Pipeline Development
Our latest epigenetics developments.
Our Pipeline Development
Nu.Q
®
Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
Breakthrough Cancer Detection Method
We have developed a novel method for liquid biopsy enabling rapid, cost-effective cancer detection in a routine blood test.
Disease Areas
Human Health
Cancer
Sepsis
Products
Nu.Q® Products
Nu.Q
®
NETs
Nu.Q
®
NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
Nu.Q
®
Discover
Buy our Nu.Q
®
Discover H3.1 Research Use Only Assay
Nu.Q
®
Vet
Nu.Q
®
Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Resources
Resources
Press Releases
Latest news on Volition and our products.
Scientific
Resources for educational and research purposes.
Events & Webinars
Resources for educational and research purposes.
Media Toolkit & Downloads
Our library for images and educational downloads.
View all resources
Company
About
Our Company
Volition means to have determination and a purpose.
Our Team
Get to know our team of experts behind our research and products.
Careers
We’re always looking for talented individuals to join our mission.
Investors
Search for:
Join Mailing List
Investor Relations
Presentations & Reports
.
Investors
Investors
Overview
News & Events
Overview
Press Releases
Video Gallery
IR Calendar
Presentations & Reports
Email Alerts
Shareholders Letters
Company Info
Company Profile
Executive Team
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Nov 14, 2025
Corporate Presentation November 2025
Sep 11, 2025
Short Corporate Deck, Sept 2025
Jul 2, 2025
Edison Spotlight Report: Nu.Q® advances in lung cancer management
Jun 23, 2025
Volition One Pager June 2025
Apr 10, 2025
A Look to the Future of Cancer Diagnostics Investor Webinar April 2025
Feb 14, 2025
Casting a new light on sepsis management Webinar, Feb 2025
Oct 22, 2024
NETs in Sepsis Management Webinar, Oct 24
Feb 13, 2024
Unravelling the web of NETs in sepsis...part II
Feb 13, 2024
Edison Spotlight Report: Snaring sepsis with early NETs detection
Nov 13, 2023
Edison Spotlight Report: Decoding the DNA of cancer Nov 2023
rss_feed
RSS
Page
1
Page
2
Next Page
arrow_forward
Select a page
Page 1
Page 2
email
Email Alerts
location_city
Company Profile
contact_page
Contacts
rss_feed
RSS News Feed
account_tree
Sitemap
